2018 was a very successful year for our team and our portfolio companies, with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact Fund and six new talented colleagues joining.
Our mission is to create and build European life sciences companies based on breakthrough innovation, with the aim of developing novel treatments that can make a major difference to patients’ lives. We combine new discoveries and entrepreneurs through two routes. The first through our preseed program under which we incubate early scientific discoveries to the point where they are ready to attract seed financing and where Novo
Seeds will lead to build syndicates of international investors. In addition to our preseed program and company creation efforts, we invest in early-stage pre-Proof of Concept biotech and medtech companies throughout Europe in size from €250 thousand to €12.5 million.